Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SC262

Cell therapy (CAR-T) · Kills target cells, directed at CD22 · developed by Sana Biotechnology

Phase 1 Most advanced trial
SANA Developer
1 Registered trials

What is SC262?

SC262 is an allogeneic CAR T-cell therapy made from CD4+ and CD8+ T-lymphocytes engineered with a chimeric antigen receptor specific for CD22, with MHC class I and II expression disrupted and CD47 expressed to reduce immune rejection. It is designed to recognize and kill CD22-expressing B-cell tumor cells and is studied in non-Hodgkin's lymphoma and large B-cell lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Cyclophosphamide, Fludarabine
Drug type
Cell therapy (CAR-T)
Targets
CD22 (antigen)
Mechanism
Kills target cells, directed at CD22
Pathways
MHC class I and II disruption (immune evasion avoidance), innate and adaptive immune response evasion
Therapy area
Oncology
Developer
Sana Biotechnology (SANA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06285422 Phase 1 Non Hodgkin's Lymphoma Active not recruiting SANA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Large B-cell LymphomaNon Hodgkin's Lymphoma

Other drugs acting on CD22

More from Sana Biotechnology

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SANA page.

Follow SANA, the company behind SC262

See SANA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SANA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.